Next Article in Journal
Integrated Process for Schizochytrium Oil Extraction, Enzymatic Modification of Lipids and Concentration of DHA Fatty Acid Esters Using Alternative Methodologies
Next Article in Special Issue
New Diterpenes and Diterpene Glycosides with Antibacterial Activity from Soft Coral Lemnalia bournei
Previous Article in Journal
Extraction, Isolation and Biological Activity of Two Glycolipids from Bangia fusco-purpurea
Previous Article in Special Issue
In Vitro Insights into the Role of 7,8-Epoxy-11-Sinulariolide Acetate Isolated from Soft Coral Sinularia siaesensis in the Potential Attenuation of Inflammation and Osteoclastogenesis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp.

1
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
2
Laboratory of Marine Drugs and Biological Products, National Laboratory for Marine Science and Technology, Qingdao 266235, China
3
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA 92093-0204, USA
4
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
*
Author to whom correspondence should be addressed.
Mar. Drugs 2024, 22(4), 145; https://doi.org/10.3390/md22040145
Submission received: 14 February 2024 / Revised: 24 March 2024 / Accepted: 24 March 2024 / Published: 26 March 2024
(This article belongs to the Special Issue Bioactive Compounds from Soft Corals and Their Derived Microorganisms)

Abstract

:
Four undescribed sesquiterpenoids, lemneolemnanes A–D (14), have been isolated from the marine soft coral Lemnalia sp. The absolute configurations of the stereogenic carbons of 14 were determined by single-crystal X-ray crystallographic analysis. Compounds 1 and 2 are epimers at C-3 and have an unusual skeleton with a formyl group on C-6. Compound 3 possesses an uncommonly rearranged carbon skeleton, while 4 has a 6/5/5 tricyclic system. Compound 1 showed significant anti-Alzheimer’s disease (AD) activity in a humanized Caenorhabditis elegans AD pathological model.

Graphical Abstract

1. Introduction

Soft corals belonging to the genus Lemnalia have long been considered as a rich source of various terpenes [1], encompassing sesquiterpenes [2], diterpenes [3,4], and diterpenoid glycosides [5,6]. Sesquiterpenes, in particular, represent a prominent class of metabolites derived from Lemnalia, exhibiting diverse carbon skeletons, including ylangane-type [7], eremophilane-type [8], nardosinane-type [9,10,11], and neolemnane-type [12], among others. Typically, neolemnane sesquiterpenes have a 6/8 bicyclic skeleton, with the potential for producing rearranged skeletons [8,13]. In addition, these sesquiterpenoids with distinct skeletons exhibited a myriad of bioactivities, such as cytotoxic [7,14], anti-inflammatory [15,16], antimicrobial [17], antiviral [10], and neuroprotective activities [18]. In summary, the investigation of sesquiterpenes in soft corals of the genus Lemnalia is of significant interest due to their structural diversity and diverse bioactivities.
In our ongoing quest for novel bioactive metabolites from soft corals, our investigation of the Lemnalia sp., which was collected from the Xisha Islands, has led to the isolation of four unreported sesquiterpenoids, lemneolemnanes A–D (14), and three that have been previously reported: 4-acetoxy-2,8-neolemnadien-5-one (5) [19], paralemnolin G (6) [20], laevinone A (7) [14] (Figure 1). Compounds 1 and 2 are epimers at C-3, featuring an unusual carbon skeleton with a formyl group on C-6. Compound 3 possesses a rearranged 6/6 carbon skeleton, while 4 exhibits a rare skeleton with a 6/5/5 tricyclic system. Compound 4 is the second compound with the 6/5/5 tricyclic skeleton [13]. Herein, we report the isolation, structural elucidation, plausible biosynthetic pathways, and anti-AD activity of these compounds.

2. Results and Discussion

Compound 1 was isolated as colourless crystals. Its optical rotation value was [α]25D + 57.8 (c 1.0, MeOH). The IR absorption peaks were found at 3415, 2808, 1728, and 1600 cm−1, indicating the presence of hydroxyl, aldehyde, ester carbonyl groups, and olefin, respectively. The molecular formula C18H26O4 was determined by HRESIMS m/z 307.1902 [M + H]+ (calcd for C18H27O4, 307.1904), implying six degrees of unsaturation. The 13C NMR spectrum (Table 1) displayed the presence of eighteen carbon signals which, in combination with the HSQC spectrum, can be classified as one aldehyde carbonyl (δC 194.0), one ester carbonyl (δC 170.8), two protonated sp2 (δC 149.7 and 129.0), two non-protonated sp2 (δC 142.8 and 139.4), one oxyquaternary sp3 (δC 76.8), one quaternary sp3 (δC 41.1), one oxymethine sp3 (δC 73.8), one methine sp3 (δC 34.4), four methylene sp3 (δC 43.6, 32.2, 27.3, and 26.3), and four methyl (δC 26.2, 22.8, 21.2, and 16.6) carbons. The 1H NMR spectrum (Table 1), in conjunction with the HSQC spectrum, displayed a singlet of the aldehydric proton at δH 9.35/δC 194.0, two olefinic protons at δH 6.21 (d, J = 5.7, 1.9 Hz)/δC 149.7 and δH 5.59 (dd, J = 5.7, 2.2 Hz)/δC 129.0, one oxymethine at δH 6.51 (d, J = 5.7 Hz)/δC 73.8, one methine at δH 2.47, m/δC 34.4, four pairs of methylene protons at δH 3.07 (d, J = 18.9 Hz) and 2.93 (d, J =18.9 Hz)/δC 32.2, δH 2.14, m and 2.04, m/δC 26.3, δH 1.87 (d, J = 15.8 Hz) and 1.42 (d, J = 15.8 Hz)/δC 43.6, and δH 1.49, m/δC 27.3, one methyl doublet at δH 0.98 (d, J = 6.7 Hz)/δC 16.6, and three methyl singlets at δH 2.15/δC 21.2, δH 1.14/δC 26.2, and δH 0.87/δC 22.8.
The planar structure of 1 was elucidated by extensive analysis of 1H–1H COSY and HMBC spectra (Figure 2). The 1H–1H COSY correlations revealed the presence of two spin systems from H-4 to H-5 and H-9 to H2-10, H2-10 to H2-11, H2-11 to H-12, and H-12 to H3-15, while the HMBC spectrum showed correlations from H3-13 to C-1, C-2, C-8, and C-12; H3-14 to C-2, C-3, and C-4; H-16 to C-5, C-6, and C-7; and H-9 to C-1, C-7, C-10, and C-11, suggesting the presence of the 6/8 neolemnane sesquiterpene scaffold. The HMBC correlations from H-4 to C-17 and H3-18 to C-17 indicated the existence of an acetoxyl group on C-4, while the correlations from H-16 to C-5, C-6, and C-7 revealed the presence of a formyl substituent on C-6. The presence of a formyl group on a sesquiterpene skeleton is not common.
The relative configuration of 1 was established by NOESY correlations (Figure 2). In the NOESY spectrum, H-5 displayed a correlation to H-16, confirming the E-configuration of the Δ5,6 double bond. NOESY cross-peaks from H3-13 to H3-15, H-2a, H3-15 to H-2a, and H3-14 to H-2a revealed that the three methyl groups were on the same face. The absence of a NOESY correlation from H-4 to H3-14 suggested that H-4 and H3-14 were on the opposite side. Thus, the relative configurations at C-1, C-3, C-4, and C-12 in 1 were established as 1R*, 3R*, 4R*, and 12S*. Finally, a suitable crystal of 1 was obtained for X-ray analysis using a diffractometer equipped with Cu Kα radiation. The Ortep diagram of 1 (Figure 3) shows the absolute configurations of C-1, C-3, C-4, and C-12 1R, 3R, 4R, and 12S, which were ascertained by a flack parameter of 0.2 (7) (Table S4).
Compound 2 was obtained as colourless crystals with an optical rotation, [α]25D +1.6 (c 1.0, MeOH). The molecular formula of 2 was determined as C18H26O4 by HRESIMS m/z 307.1898 [M + H]+ (calcd for C18H27O4, 307.1904), which is the same as that of 1. The 1H and 13C NMR spectra (Table 1) of 2 closely resembled those of 1, with some chemical shift changes around the chiral C-3, suggesting that 2 could be a stereoisomer of 1. Furthermore, the HMBC correlations and 1H–1H COSY cross-peaks (Figure 2) confirmed that the planar structure of 2 was the same as that of 1.
In the NOESY spectrum (Figure 2), H-5 displayed a correlation to H-16, consistent with the E-configuration of the Δ5,6 double bond. The NOESY correlations from H3-13 to H-2a, H2-11, H3-15 to H-2a, H2-11, revealed that the two methyl groups were on the same face. In addition, the NOESY correlations from H-4 to H3-14 and H-12 to H3-14 indicated that H-4, H3-14, and H-12 were on the same side. Thus, the relative configuration at C-3 in 2 was different from that in 1, and the relative configurations at C-1, C-3, C-4, and C-12 in 2 were established as 1R*, 3S*, 4R*, and 12S*. Ultimately, the absolute configurations at C-1, C-3, C-4 and C-12 in 2 were established as 1R, 3S, 4R, and 12S [Flack parameter of 0.02(6)] (Table S5) by the single-crystal X-ray diffraction experiment (Figure 3). Therefore, 1 and 2 are epimers at C-3.
Compound 3 was isolated as colourless crystals and its molecular formula C18H26O5 was determined by the HRESIMS m/z 345.1670 [M + Na]+ (calcd for C18H26O5Na, 345.1672), requiring six degrees of unsaturation. Compound 3 was levorotatory, with [α]25D −10.8 (c 1.0, MeOH). The 13C NMR spectrum (Table 2) displayed the presence of eighteen carbon signals which, in combination with the HSQC spectrum, can be classified as two ester carbonyl (δC 173.5 and 170.3), one protonated sp2 (δC 132.5), one non-protonated sp2 (δC 128.7), one oxyquaternary sp3 (δC 63.1), one quaternary sp3 (δC 37.6), two oxymethine sp3 (δC 72.1 and 65.0), two methine sp3 (δC 43.7 and 39.5), three methylene sp3 (δC 32.6, 26.4, and 24.6), one methoxy (δC 51.7) and four methyl (δC 20.9, 18.8, 16.0, and 15.4) carbons. The 1H NMR spectrum (Table 2), in conjunction with the HSQC spectrum, displayed a singlet of the olefinic proton at δH 5.58/δC 149.7, two oxymethine at δH 5.68 (d, J = 5.3 Hz)/δC 72.1 and δH 3.15, m/δC 65.0, two methine at δH 2.24, m/δC 43.7 and δH 1.06, m/δC 39.5, three pairs of methylene protons at δH 2.60, m/δC 32.6, δH 2.03, m and 1.74, m/δC 26.4 and δH 1.30, m and 1.08, m/δC 24.6, one methyl doublet at δH 0.80 (d, J = 6.8 Hz)/δC 15.4, and four methyl singlets at δH 3.65/δC 51.7, δH 1.99/δC 20.9, δH 1.66/δC 18.8, and δH 0.92/δC 16.0.
The 1H–1H COSY correlations (Figure 2) from H-4 to H-5, H-5 to H-6, and H-9 to H2-10, H2-10 to H2-11, H2-11 to H-12, and H-12 to H3-15 revealed the presence of two spin systems, and together with the HMBC correlations (Figure 2) from H3-13 to C-1, C-2, C-8, and C-12; H3-14 to C-2, C-3, and C-4; and H-9 to C-5 and C-8, enabling the construction of an adecalin scaffold. In addition, the HMBC correlations from H-4 to C-17 and H3-18 to C-17 indicated the existence of an acetoxy group on C-4. The presence of a carbomethoxy on C-7 was supported by the HMBC correlations from H-6 to C-7 and H3-16 to C-7. The established planar structure of 3 has the same decalin scaffold as other nardosinane-type sesquiterpenoids, but differs from previously reported nardosinanes by the presence of the 2-ethoxy-2-methyl-2-oxoethyl group.
The relative configurations of 3 were partially established by the NOESY spectrum (Figure 2). The NOESY correlations from H-2 to H3-14 indicated the Z-configuration of the Δ2,3 double bond. The correlation from H3-13 to H3-15 in the NOESY spectrum indicated that Me-13 and Me-15 are cofacial. And the NOESY correlations from H-5 to H-4, H-9, and H-9 to H-10a, and H-12 to H-10a, showed that H-4, H-5, H-9, and H-12 are on the same side. Only the relative configuration of C-8 remained undetermined by the NOESY correlations. Since 3 could be obtained as a suitable crystal, the absolute configurations at C-1, C-4, C-5, C-8, C-9, and C-12 in 3 were determined as 1S, 4R, 5S, 8S, 9R, and 12S by a single-crystal X-ray diffraction experiment. Figure 3 shows the Ortep diagram of 3 with a Flack parameter of 0.04 (7) (Table S6).
Compound 4 was obtained as colourless crystals and is dextrorotatory, [α]25D +181.9 (c 1.0, MeOH). The molecular formula of 3 was established as C15H20O3 by HRESIMS m/z 249.1485 [M + H]+ (calcd for C15H21O3, 249.1485), requiring six degrees of unsaturation. The 13C NMR spectrum (Table 3) displayed the presence of fifteen carbon signals which, in combination with the HSQC spectrum, can be classified as two ketone carbonyl (δC 217.8 and 211.0), one protonated sp2 (δC 141.0), one non-protonated sp2 (δC 137.6), one oxyquaternary sp3 (δC 93.6), two quaternary sp3 (δC 57.6 and 51.6), one methine sp3 (δC 39.4), four methylene sp3 (δC 43.9, 42.9, 33.7, and 30.3) and three methyl (δC 16.2, 12.1, and 11.0) carbons. The 1H NMR spectrum (Table 3), in conjunction with the HSQC spectrum, displayed one olefinic proton at δH 5.73 (d, J = 1.7 Hz)/δC 141.0, one methine at δH 2.28, m/δC 39.4, four pairs of methylene protons at δH 2.73 (d, J = 16.1 Hz) and 2.10, m/δC 42.9, δH 2.36, m and 2.22, m/δC 33.7, δH 2.22, m and 2.13, m/δC 43.9 and δH 2.00, m and 1.71, m/δC 30.3, two methyl doublets at δH 1.61 (d, J = 1.6 Hz)/δC 12.1 and δH 0.95 (d, J = 6.8 Hz)/δC 16.2, one methyl singlet at δH 1.04/δC 11.0, and a singlet of the hydroxyl proton δH 3.20. The 1H NMR signal at δH 5.73 (d, d, J = 1.7 Hz), along with the carbon signals at δC 141.0, 137.6, 217.8, and 211.0 indicated the presence of one trisubstituted double bond and two ketone groups, respectively. Thus, the remaining three degrees of unsaturation indicated the existence of a tricyclic system in 4.
Firstly, the 1H–1H COSY correlations (Figure 2) from H2-11 to H-12 and from H-12 to H3-15 and the HMBC correlations (Figure 2) from H3-13 to C-1, C-2, C-8 and C-12; H3-14 to C-2, C-3, and C-4; and H-9 to C-1, C-8, C-10, and C-11 constructed a 6/5 ring system. Furthermore, the 1H−1H COSY correlations from H-6 to H-7, in combination with the HMBC correlations from H-6 to C-5 and C-8 and 4-OH to C-4, C-5, and C-8 indicated the presence of a cyclopentanone ring fused with the cyclohexene ring. Consequently, the planar structure of 4 was elucidated as a 6/5/5 ring system.
The NOESY spectrum (Figure 2) showed correlations from H3-13 to H3-15, suggesting that H3-13 and H3-15 are on the same face of the molecule. Moreover, the NOESY correlation between H3-13 and H2-7 revealed that H3-13 and H2-7 are on the same face. The absolute configurations of C-1, C-4, C-8, and C-12 in 4 were established as 1S, 4R, 8S, and 12S which was confirmed by a single-crystal X-ray diffraction experiment (Figure 3) with the Flack parameter of −0.1(2) (Table S7).
Based on the structural features of 14, we postulated that these compounds were originated from the same precursor 5 (Scheme 1). First, the methylation of 5 led to the formation of intermediate 1a. Then, 1a was converted to the intermediate 1c by the reduction of the C-5 carbonyl of 1a to the 5-hydroxyl group in 1b, followed by dehydration of 1b to give a double bond in 1c. The hydroxylation of Me-16 of 1c led to the formation of a primary alcohol in 1d which, after oxidation, gave an aldehyde functionality at C-6 in 1e. Finally, hydroxylation of the C2/C3 double bond in 1e led to the formation of 1 and 2. This was due to the fact that C-3 could form a more stable carbocation (tertiary) than C-2, and nucleophilic addition would occur via the SN1 mechanism, resulting in the formation of two isomers with opposite configurations. Compound 3 originated from the intermediate 3a, a hydroxylation product of 5 at C-7. Compound 3a was oxidized at C-7 to the form 3b, which was converted to 3c by the epoxidation of C-8/C-9. The dehydrogenation of 3c at C-4 was cyclized at C-7/C-4 to form 3d. Then, 3d was converted to the lactone product 3e via Baeyer–Villiger oxidation. Compound 3e was converted to 3f by hydrolysis, followed by the dehydration and reduction of 3f to form the intermediate 3g. Finally, the methylation of 3g led to the formation of 3, while in the proposed biosynthetic pathway of compound 4, the precursor 4a was the hydroxylation product of 5 at C-10. Then, 4a was converted to the intermediate 4b by the oxidation of C-10. The dehydrogenation of 4b at C-4 induced subsequent cyclization of C-4/C-8 which led to the formation of the intermediate 4c, which was converted to the form 4 by the deacetylation of C-4.
Compounds 14 were first screened for cytotoxic and anti-inflammatory properties. However, none of the compounds showed significant anti-inflammatory activity in CuSO4-induced transgenic fluorescent zebrafish, or cytotoxic activity. Furthermore, 14 were evaluated for anti-AD activity using the transgenic Caenorhabditis elegans model. Memantine was used as a positive control due to its ability to reduce amyloid β (Aβ) peptide levels in human neuroblastoma cells, as well as to inhibit Aβ oligomer-induced synaptic loss [21], which effectively alleviates AD-like symptoms in worms [22]. Surprisingly, at a concentration of 100 μM/L, 1 significantly alleviated AD-like symptoms in the worm model (p < 0.05) (Figure 4). This result suggests that 1 has the potential to be a candidate for the development of an anti-AD agent based on its observed biological activity.

3. Materials and Methods

3.1. General Experimental Procedures

Melting points were measured on a microscopic melting point apparatus (Shanghai Zhuoguang Technology Company Limited, Shanghai, China). Optical rotations were measured on a Jasco P-1020 digital polarimeter (Jasco, Tokyo, Japan). The UV spectra were recorded on a Beckman DU640 spectrophotometer (Beckman Ltd., Shanghai, China). CD spectra were obtained on a Jasco J-810 spectropolarimeter (Jasco, Tokyo, Japan). IR (KBr) spectra were taken on a Nicolet NEXUS 470 spectrophotometer in KBr discs (Thermo Scientific, Beijing, China). NMR spectra were recorded using the Agilent 500 MHz (Agilent, Beijing, China), (1H, 500 MHz; 13C, 125 MHz) or the Bruker AVANCE NEO 400 (1H, 400 MHz; 13C, 100 MHz), (Bruker, Faellanden, Switzerland). The 7.26 ppm and 77.16 ppm resonances of CDCl3 were used as internal references for the 1H and 13C NMR spectra, respectively. HRESIMS spectra were measured on Micromass Q-Tof Ultima GLOBAL GAA076LC mass spectrometers (Autospec-Ultima-TOF, Waters, Shanghai, China). The crystallographic data were obtained on a Bruker APEX-II CCD diffractometer (Bruker, Beijing, China) equipped with graphite-monochromatized Cu Kα radiation. Semi-preparative HPLC was performed using a Waters 1525 pump (Waters, Singapore) equipped with a 2998 photodiode array detector and a SilGreen C18 column (SilGreen, 10 × 250 mm, 5 μm). Silica gel (200–300 mesh and 300–400 mesh), (Qingdao Marine Chemical Factory, Qingdao, China) was used for column chromatography. Chiral HPLC analysis and resolution were conducted on a chiral analytical column (Daicel, Shanghai, China).

3.2. Animal Material

The soft coral Lemnalia sp. was collected from Xisha Island (Yagong Island) of the South China Sea in 2014, and was frozen immediately after collection. The specimen was identified by Prof Ping-Jyun Sung, Institute of Marine Biotechnology, National Museum of Marine Biology & Aquarium, Pingtung 944, Taiwan. The voucher specimen (No. xs-yg-12) was deposited at the State Key Laboratory of Marine Drugs, Ocean University of China, People’s Republic of China.

3.3. Extraction and Isolation

A frozen specimen of Lemnalia sp. (7.20 kg, wet weight) was thawed, homogenized, and then exhaustively extracted with CH3OH six times (3 days each time) at room temperature. The combined solutions were concentrated in vacuo and were subsequently desalted by redissolving in CH3OH to yield a residue (175.18 g). The crude extract was subjected to silica gel vacuum column chromatography and eluted with a gradient of petroleum ether/acetone (100:1 to 1:1, v/v) and subsequently eluted with a gradient of CH2Cl2/MeOH (10:1 to 1:1, v/v) to obtain sixteen fractions (Frs.1–16). Each fraction was detected by TLC. Fr.2 was subjected to silica gel vacuum column chromatography and eluted with petroleum ether/acetone, from 100:1 to 1:1, v/v, to give three subfractions Sfrs.2.1–2.3. Sfr.2.2 was purified by reversed-phase HPLC (OD-H, MeOH/H2O = 80/20, flow rate = 1.5 mL/min, I = 210 nm) to afford 5 (28.8 mg, tR = 36 min). Fr.4 was subjected to silica gel vacuum column chromatography and eluted with petroleum ether/acetone, from 80:1 to 1:1, v/v, to give seven subfractions Sfrs.4.1–4.7. Sfr.4.5 was purified by reversed-phase HPLC (OD-H, MeOH/H2O = 70/30, flow rate = 1.5 mL/min, I = 210 nm) to afford mixtures of 3 and 6 (24.6 mg, tR = 42 min). The mixture of 3 was purified with a chiral column (Daicel Chiral pack IC, n-hexane/isopropanol = 60:40, flow rate = 1.0 mL/min, I = 210 nm) to give 3 (11.9 mg, tR = 36 min). Fr.7 was subjected to silica gel vacuum column chromatography and eluted with petroleum ether/acetone, from 50:1 to 1:1, v/v, to give five subfractions Sfrs.7.1–7.5. Sfr.7.2 was purified by reversed-phase HPLC (OD-H, MeCN/H2O = 50/50, flow rate = 1.5 mL/min, I = 320 nm) to afford 1 (7.1 mg, tR = 72 min). Fr.9 was subjected to silica gel vacuum column chromatography and eluted with petroleum ether/acetone, from 30:1 to 1:1, v/v, to give four subfractions Sfrs.9.1–9.4. Sfr.9.4 was purified by reversed-phase HPLC (OD-H, MeOH/H2O = 60/40, flow rate = 1.5 mL/min, I = 210 nm) to afford 7 (19.7 mg, tR = 45 min). Fr.11 was subjected to silica gel vacuum column chromatography and eluted with petroleum ether/acetone, from 20:1 to 1:1, v/v, to give six subfractions Sfrs.11.1–11.6. Sfr.11.1 was purified by reversed-phase HPLC (OD-H, MeCN/H2O = 30/70, flow rate = 1.5 mL/min, I = 210 nm) to afford 4 (20.7 mg, tR = 57 min). Sfr.11.2 was purified by reversed-phase HPLC (OD-H, MeCN/H2O = 50/50, flow rate = 1.5 mL/min, I = 320 nm) to afford 2 (7.3 mg, tR = 45 min).
Lemneolemnane A (1): colourless crystals, mp 157.9–159.5 °C; [α]25D +57.8 (c 1.0, MeOH); CD (c 1.0, MeOH) = Δε197 + 51.50, Δε226–50.33, Δε260 + 17.29; UV (MeOH) λmax (log ε) = 196 (1.45) nm, λmax (log ε) = 213(0.91) nm, λmax (log ε) = 230(1.42) nm; IR (KBr) νmax = 3415, 2808, 1728, 1600 cm−1; HRESIMS m/z 307.1902 [M + H]+ (calcd for C18H27O4, 307.1904). For 1H NMR and 13C NMR data, see Table 1.
Lemneolemnane B (2): colourless crystals, mp 186.5–188.3 °C; [α]25D +1.6 (c 1.0, MeOH); CD (c 0.5, MeOH) = Δε199 + 70.30, Δε225–83.68, Δε255 + 17.48; UV (MeOH) λmax (log ε) = 196 (1.62) nm, λmax (log ε) = 212(1.16) nm, λmax (log ε) = 226(1.66) nm; IR (KBr) νmax = 3431, 2831, 1726, 1599 cm−1; HRESIMS m/z 307.1898 [M + H]+ (calcd for C18H27O4, 307.1904). For 1H NMR and 13C NMR data, see Table 1.
Lemneolemnane C (3): colourless crystals, mp 135.6–137.9 °C; [α]25D −10.8 (c 1.0, MeOH); CD (c 0.5, MeOH) = Δε201 + 18.60; UV (MeOH) λmax (log ε) = 195 (1.99) nm, λmax (log ε) = 193(0.96) nm; IR (KBr) νmax = 1641 cm−1; HRESIMS m/z 323.1854 [M + H]+ (calcd for C18H27O5, 323.1853) and 345.1670 [M + Na]+ (calcd. for C18H26O5Na, 345.1672). For 1H NMR and 13C NMR data, see Table 2.
Lemneolemnane D (4): colourless crystals, mp 176.3–177.8 °C; [α]25D +181.9 (c 1.0, MeOH); CD (c 0.5, MeOH) = Δε198 + 43.31, Δε231–35.02, Δε309 + 72.61; UV (MeOH) λmax (log ε) = 193 (1.15) nm, λmax (log ε) = 208 (0.78) nm, λmax (log ε) = 218 (0.80) nm; IR (KBr) νmax = 3415, 1716 cm−1; HRESIMS m/z 249.1485 [M + H]+ (calcd for C15H21O3, 249.1485) and 266.1751 [M + NH4]+ (calcd. for C15H24O3 N, 266.1751). For 1H NMR and 13C NMR data, see Table 3.

3.4. Anti-Alzheimer’s Disease Activity

The transgenic Caenorhabditis elegans strain CL4176 with genotype smg-1ts (myo-3/Aβ1-42 long 3′-untranslated region (UTR)) was obtained from the Caenorhabditis Genetics Center (CGC) (University of Minnesota, Minneapolis, MN, USA). Worms were routinely cultured on nematode growth medium (NGM) plates for 72 h to grow to the L3 stage at 16 °C, using Escherichia coli OP50 as the standard food resource. Throughout the bioactivity assays, 60~80 worm eggs were placed on NGM containing 100 μM/L of the test compounds, 100 μM/L memantine as a positive control, and 0.1% dimethyl sulfoxide solvent as a negative control. When the worms grew into L3 larvae, they were then transferred into another incubator which was set at 25 °C for another 32 h. Paralysed worms were observed and counted under a dissecting microscope every 2 h until all worms were paralysed. The anti-AD activity of the tested compound was indicated by the percentage of individual paralyzed worms in the tested worm population throughout the whole experiment in contrast with the negative control group. For the anti-AD activity assay, a log-rank survival test was used to compare the significance among treatments. p values at 0.05 or lower were considered statistically significant.

3.5. X-ray Crystallographic Analysis

X-ray crystallographic data were collected on a Bruker APEX-II CCD diffractometer. The crystal was kept at 150.0 K or 293.0 K during data collection. Using Olex2, the structures were solved with the SHELXT structure solution program using intrinsic phasing and refined with the SHELXL refinement package using least squares minimization.

4. Conclusions

Soft corals belonging to the genus Lemnalia have been recognized as a rich source of various bioactive secondary metabolites. Our continuing chemical investigation of the Xisha soft coral Lemnalia sp. resulted in the isolation of four unreported sesquiterpenoids, lemneolemnanes A–D (14), together with three previously described sesquiterpenoids 57. Compounds 1 and 2 are epimers at C-3 that have an unusual skeleton with a formyl group on C-6. Based on the proposed biosynthetic pathways, 1 and 2 could be artifacts originating from a hydration of the C-2 and C-3 double bond of the octacyclic ring of the intermediate after formylation. Compound 3 features a decalin scaffold and a 2-ethoxy-2-methyl-2-oxoethyl group, while 4 possesses a 6/5/5 tricyclic system. Based on the structural characterization of lemneolemnanes A–D (14), we hypothesized their possible biosynthetic pathways, originating from 5. Compound 1 showed significant anti-Alzheimer’s disease (AD) activity in a Caenorhabditis elegans model. The above research enriches chemical libraries of the soft corals Lemnalia sp. and provides some references in further exploration of potential biological activity. Meanwhile, the discovery of these rare molecular structures will provide new ideas.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md22040145/s1, Tables S1–S4: NMR data of 14; Tables S5–S8 and Figures S1–S4: X-ray crystallographic analyses of 14; Figures S5–S42: NMR spectra of 17.

Author Contributions

P.-L.L. designed the experiments, supervised, and acquired funding; Y.Z. (Yuan Zong) performed the experiments, isolated the compounds, and analysed the spectral data; Y.Z. (Yuan Zong), T.-Y.J., J.-J.Y., and K.-Y.W. prepared the Supplementary Materials; X.S. and Y.Z. (Yue Zhang) recorded data.; Yuan Zong. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China, grant number 42276088.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Data are contained within the article or Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Wu, Q.; Sun, J.; Chen, J.; Zhang, H.; Guo, Y.W.; Wang, H. Terpenoids from Marine Soft Coral of the Genus Lemnalia: Chemistry and Biological Activities. Mar. Drugs. 2018, 16, 320. [Google Scholar] [CrossRef]
  2. Wu, Q.; Ye, F.; Li, X.L.; Liang, L.F.; Sun, J.; Sun, H.; Guo, Y.W.; Wang, H. Uncommon Polyoxygenated Sesquiterpenoids from South China Sea Soft Coral Lemnalia flava. J. Org. Chem. 2019, 84, 3083–3092. [Google Scholar] [CrossRef] [PubMed]
  3. Yan, X.; Ouyang, H.; Wang, W.; Liu, J.; Li, T.; Wu, B.; Yan, X.; He, S. Antimicrobial Terpenoids from South China Sea Soft Coral Lemnalia sp. Mar. Drugs. 2021, 19, 294. [Google Scholar] [CrossRef] [PubMed]
  4. Wu, Q.; Li, H.; Yang, M.; Jia, A.Q.; Tang, W.; Wang, H.; Guo, Y.W. Two new cembrane-type diterpenoids from the xisha soft coral Lemnalia flava. Fitoterapia 2019, 134, 481–484. [Google Scholar] [CrossRef] [PubMed]
  5. Yan, X.; Ouyang, H.; Li, T.; Shi, Y.; Wu, B.; Yan, X.; He, S. Six New Diterpene Glycosides from the Soft Coral Lemnalia bournei. Mar. Drugs. 2021, 19, 339. [Google Scholar] [CrossRef] [PubMed]
  6. Yao, G.M.; Vidor, N.B.; Foss, A.P.; Chang, L.C. Lemnalosides A-D, Decalin-Type Bicyclic Diterpene Glycosides from the Marine Soft Coral Lemnalia sp. J. Nat. Prod. 2007, 70, 901–905. [Google Scholar] [CrossRef] [PubMed]
  7. Xio, Y.J.; Su, J.H.; Chen, B.W.; Tseng, Y.J.; Wu, Y.C.; Sheu, J.H. Oxygenated ylangene-derived sesquiterpenoids from the soft coral Lemnalia philippinensis. Mar. Drugs 2013, 11, 3735–3741. [Google Scholar] [CrossRef]
  8. Xio, Y.J.; Su, J.H.; Tseng, Y.J.; Chen, B.W.; Liu, W.; Sheu, J.H. Oxygenated eremophilane- and neolemnane-derived sesquiterpenoids from the soft coral Lemnalia philippinensis. Mar. Drugs 2014, 12, 4495–4503. [Google Scholar] [CrossRef] [PubMed]
  9. Liu, J.; Xia, F.; Ouyang, H.; Wang, W.; Li, T.; Shi, Y.; Yan, X.; Yan, X.; He, S. Nardosinane-related antimicrobial terpenoids from Lemnalia sp. soft coral. Phytochemistry 2022, 196, 113088. [Google Scholar] [CrossRef]
  10. Liu, M.; Li, P.L.; Tang, X.L.; Luo, X.C.; Liu, K.C.; Zhang, Y.; Wang, Q.; Li, G.Q. Lemnardosinanes A-I: New Bioactive Sesquiterpenoids from Soft Coral Lemnalia sp. J. Org. Chem. 2021, 86, 970–979. [Google Scholar] [CrossRef]
  11. Wang, Q.; Tang, X.L.; Liu, H.; Luo, X.C.; Sung, P.J.; Li, P.L.; Li, G.Q. Clavukoellians G-K, New Nardosinane and Aristolane Sesquiterpenoids with Angiogenesis Promoting Activity from the Marine Soft Coral Lemnalia sp. Mar. Drugs 2020, 18, 171. [Google Scholar] [CrossRef] [PubMed]
  12. Liu, M.Y.; Li, P.L.; Luo, X.C.; van Ofwegen, L.; Tang, X.L.; Li, G.Q. Sesquiterpenoids from the soft coral Lemnalia sp. Nat. Prod. Res. 2021, 35, 3752–3756. [Google Scholar] [CrossRef] [PubMed]
  13. Han, X.; Wang, Q.; Luo, X.C.; Tang, X.L.; Wang, Z.; Zhang, D.; Cao, S.G.; Li, P.L.; Li, G.Q. Lemnalemnanes A-C, Three Rare Rearranged Sesquiterpenoids from the Soft Corals Paralemnalia thyrsoides and Lemnalia sp. Org. Lett. 2022, 24, 11–15. [Google Scholar] [CrossRef] [PubMed]
  14. El-Gamal, A.A.H.; Chiu, E.P.; Li, C.H.; Cheng, S.Y.; Dai, C.F.; Duh, C.Y. Sesquiterpenoids and Norsesquiterpenoids from the Formosan Soft Coral Lemnalia laevis. J. Nat. Prod. 2005, 68, 1749–1753. [Google Scholar] [CrossRef] [PubMed]
  15. CHENG, S.Y.; LIN, E.H.; HUANG, J.S.; WEN, Z.H.; Duh, C.Y. Ylangene-Type and Nardosinane-Type Sesquiterpenoids from the Soft Corals Lemnalia flava and Paralemnalia thyrsoides. Chem. Pharm. Bull. 2010, 58, 381–385. [Google Scholar] [CrossRef] [PubMed]
  16. Jean, Y.H.; Chen, W.F.; Duh, C.Y.; Huang, S.Y.; Hsu, C.H.; Lin, C.S.; Sung, C.S.; Chen, I.M.; Wen, Z.H. Inducible nitric oxide synthase and cyclooxygenase-2 participate in anti-inflammatory and analgesic effects of the natural marine compound lemnalol from Formosan soft coral Lemnalia cervicorni. Eur. J. Pharmacol. 2008, 578, 323–331. [Google Scholar] [CrossRef] [PubMed]
  17. Phan, C.S.; Kamada, T.; Hatai, K.; Vairappan, C.S.; Paralemnolins, V.W. New Nardosinane-Type Sesquiterpenoids from a Bornean Soft Coral, Lemnalia sp. Chem. Nat. Compd. 2018, 54, 903–906. [Google Scholar] [CrossRef]
  18. Lu, Y.; Li, P.J.; Hung, W.Y.; Su, J.H.; Wen, Z.H.; Hsu, C.H.; Dai, C.F.; Chiang, M.Y.; Sheu, J.H. Nardosinane sesquiterpenoids from the Formosan soft coral Lemnalia flava. J. Nat. Prod. 2011, 74, 169–174. [Google Scholar] [CrossRef]
  19. Jurek, J.; Scheuer, P. Sesquiterpenoids and norsesquiterpenoids from the soft coral lemnalia africana. J. Nat. Prod. 1993, 56, 508–513. [Google Scholar] [CrossRef]
  20. Huang, H.C.; Chao, C.H.; Su, J.H.; Hsu, C.H.; Chen, S.P.; Kuo, Y.H.; Shue, J.H. Neolemnane-Type Sesquiterpenoids from a Formosan Soft Coral Paralemnalia thyrsoides. Chem. Pharm. Bull. 2007, 55, 876–880. [Google Scholar] [CrossRef]
  21. Scholtzova, H.; Wadghiri, Y.Z.; Douadi, M.; Sigurdsson, E.M.; Li, Y.S.; Quartermain, D.; Banerjee, P.; Wisniewski, T. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer’s-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res. 2008, 86, 2784–2791. [Google Scholar] [CrossRef] [PubMed]
  22. Xin, L.; Yamujala, R.; Wang, Y.; Wang, H.; Wu, W.H.; Lawton, M.A.; Long, C.; Di, R. Acetylcholineestarase-inhibiting alkaloids from Lycoris radiata delay paralysis of amyloid beta-expressing transgenic C. elegans CL4176. PLoS ONE 2013, 8, e63874. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Structures of 17.
Figure 1. Structures of 17.
Marinedrugs 22 00145 g001
Figure 2. Key HMBC correlations (red arrows), 1H–1H COSY correlations (thick black line), and NOESY correlations (dotted arrow) of 14.
Figure 2. Key HMBC correlations (red arrows), 1H–1H COSY correlations (thick black line), and NOESY correlations (dotted arrow) of 14.
Marinedrugs 22 00145 g002
Figure 3. ORTEP diagrams of 14 (displacement ellipsoids are drawn at the 50% probability level).
Figure 3. ORTEP diagrams of 14 (displacement ellipsoids are drawn at the 50% probability level).
Marinedrugs 22 00145 g003
Scheme 1. Proposed biosynthetic pathways of 14.
Scheme 1. Proposed biosynthetic pathways of 14.
Marinedrugs 22 00145 sch001
Figure 4. Anti-Alzheimer’s disease (AD) activity of 1 (worms were treated with 100 μM/L of 1, 100 μM/L memantine was used as a positive control, and 0.1% dimethyl sulfoxide was used as a negative control).
Figure 4. Anti-Alzheimer’s disease (AD) activity of 1 (worms were treated with 100 μM/L of 1, 100 μM/L memantine was used as a positive control, and 0.1% dimethyl sulfoxide was used as a negative control).
Marinedrugs 22 00145 g004
Table 1. 1H NMR (500 MHz) and 13C NMR (125 MHz) data for 12 in CDCl3.
Table 1. 1H NMR (500 MHz) and 13C NMR (125 MHz) data for 12 in CDCl3.
NO.12
δC TypeδH (J in Hz)δC TypeδH (J in Hz)
141.1, C 40.7, C
2a43.6, CH21.87 d (15.8)46.2, CH21.87 d (15.1)
2b1.42 d (15.8)1.61 d (15.1)
376.8, C 77.0, C
473.8, CH6.51 d (5.6)73.7, CH6.34 d (5.6)
5149.7, CH6.21 dt (5.6; 1.9)150.2, CH6.30 dt (5.6; 1.9)
6142.8, C 142.6, C
7a32.2, CH23.07 d (18.9)32.6, CH23.03 m
7b2.93 d (18.9)3.03 m
8139.4, C 139.1, C
9129.0, CH5.59 dd (5.7; 2.2)129.4, CH5.62 d (3.7)
10a26.3, CH22.14 m26.0, CH22.13 m
10b2..04 m2..03 m
11a27.3, CH21.49 m27.3, CH21.52 m
11b1.49 m1.52 m
1234.4, CH2.47 m34.2, CH2.00 m
1322.8, CH30.87 s22.9, CH30.92 s
1426.2, CH31.14 s27.2, CH31.44 s
1516.6, CH30.98 d (6.7)16.5, CH30.96 d (6.7)
16194.0, CH9.35 s194.1, C9.38 s
17170.8, C 170.4, C
1821.2, CH32.15 s21.1, CH32.16 s
Table 2. 1D and 2D NMR data for 3 in CDCl3.
Table 2. 1D and 2D NMR data for 3 in CDCl3.
NO.3
δC a TypeδH b (J in Hz)1H–1H COSYHMBCNOESY
137.6, C
2132.5, CH5.58 s C-1, C-4, C-8, C-12, C-13, C-14H3-14
3128.7, C
472.1, CH5.68 d (5.3)H-5C-2, C-3, C-5, C-6, C-17H-5
543.7, CH2.24 mH-4, H-6C-1, C-3, C-4, C-6, C-7, C-8, C-9H-4, H-9
6a32.6, CH22.60 mH-5C-4, C-5, C-7, C-8
6b2.60 m
7173.5, C
863.1, C
965.0, CH3.15 mH-10aC-5, C-8, C-10, C-11H-5, H-10a
10a26.4, CH21.74 mH-9, H2-11C-8, C-9, C-11, C-12H-9, H-12
10b2.03 m
11a24.6, CH21.30 mH2-10, H-12C-1, C-9, C-10, C-12, C-15
11b1.08 m
1239.5, CH1.06 mH-11, H3-15C-1, C-2, C-11, C-13, C-15H-10a
1316.0, CH30.92 s C-1, C-2, C-8, C-12H3-15
1418.8, CH31.66 s C-2, C-3, C-4H-2
1515.4, CH30.80 d (6.8)H-12C-1, C-11, C-12H3-13
1651.7, CH33.65 s C-7
17170.3, C
1820.9, CH31.99 s C-17
a Recorded at 125 MHz. b Recorded at 500 MHz.
Table 3. 1D and 2D NMR data for 4 in CDCl3.
Table 3. 1D and 2D NMR data for 4 in CDCl3.
NO.4
δC a TypeδH b (J in Hz)1H–1H COSYHMBCNOESY
151.6, C
2141.0, CH5.73 d (1.7) C-1, C-3, C-4, C-8, C-13, C-14H3-13, H3-15
3137.6, C
493.6, C
5217.8, C
6a33.7, CH22.36 mH-6C-5, C-7, C-8
6b2.22 m
7a30.3, CH22.00 mH-7C-1, C-4, C-5, C-6, C-8, C-9
7b1.71 m
857.6, C
9a42.9, CH22.73 d (16.1) C-1, C-4, C-7, C-8, C-10, C-11
9b2.10 m
10211.0, C
11a43.9, CH22.22 mH-12C-1, C-10, C-12, C-15
11b2.13 m
1239.4, CH2.28 mH-11, H-15C-1, C-2, C-10, C-11, C-13, C-15
1311.0, CH31.04 s C-1, C-2, C-8, C-12H-7, H3-15
1412.1, CH31.61 d (1.6) C-2, C-3, C-4H3-14
1516.2, CH30.95 d (6.8)H-12C-1, C-11, C-12H3-13
OH 3.20 s C-4, C-5, C-8
a Recorded at 125 MHz. b Recorded at 500 MHz.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zong, Y.; Jin, T.-Y.; Yang, J.-J.; Wang, K.-Y.; Shi, X.; Zhang, Y.; Li, P.-L. Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp. Mar. Drugs 2024, 22, 145. https://doi.org/10.3390/md22040145

AMA Style

Zong Y, Jin T-Y, Yang J-J, Wang K-Y, Shi X, Zhang Y, Li P-L. Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp. Marine Drugs. 2024; 22(4):145. https://doi.org/10.3390/md22040145

Chicago/Turabian Style

Zong, Yuan, Tian-Yun Jin, Jun-Jie Yang, Kun-Ya Wang, Xing Shi, Yue Zhang, and Ping-Lin Li. 2024. "Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp." Marine Drugs 22, no. 4: 145. https://doi.org/10.3390/md22040145

APA Style

Zong, Y., Jin, T. -Y., Yang, J. -J., Wang, K. -Y., Shi, X., Zhang, Y., & Li, P. -L. (2024). Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp. Marine Drugs, 22(4), 145. https://doi.org/10.3390/md22040145

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop